Class 1.1 new drug of HongRi Pharmaceutical Co., Ltd. is about to obtain clinical approval

According to the website of the State Food and Drug Administration (CFDA) on May 8, the declared clinical status of the 1.1 chemical drug of HongRi Pharmaceutical Co., Ltd., the raw material drug of picolamine mesylate B and picolamine mesylate B for injection, was changed to "under approval" According to the people familiar with the matter, the drug is the KB project of the company, and it is expected to obtain the clinical approval documents in about two months KB, as a class 1.1 new drug, was jointly developed by HongRi pharmaceutical and the First Affiliated Hospital of the Third Military Medical University of the people's Liberation Army It is worth mentioning that this variety is similar to the indications of Xuebijing injection, the main variety of HongRi pharmaceutical, which is used to treat sepsis Xuebijing injection accounts for about 48% of the income of HongRi pharmaceutical industry More than 18 million people suffer from sepsis and more than one million people die every year It is a worldwide medical problem that there is no ideal therapeutic drug in clinic HongRi pharmaceutical executives have said that the KB project is a heavy variety in the company's "R & D pool", which, in cooperation with the company's main variety Xuebijing injection, is deeply involved in the field of pyemia treatment